Stocks News

LAST PRICE
44.2700
TODAY'S CHANGE (%)
Trending Down-0.4600 (-1.0284%)

Bid / Lots
---/ ---
Ask / Lots
---/ ---
Open / Previous Close
45.1300 / 44.7300
Day Range
Low 43.6200
High 46.0350
52 Week Range
Low 23.1400
High 48.8900
Volume
544,613
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 14, 2024
- Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: MIRM
  
  for the fiscal year ended December 31, 2023 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors," as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov.
Nov 13, 2024
- DJ Mirum Pharmaceuticals Price Target Maintained With a $66.00/Share by HC Wainwright & Co., from 2:06PM ET on Wednesday Nov 13, 2024 by Dow Jones
  2:06PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: MIRM
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/MIRM/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 13, 2024 14:06 ET (19:06 GMT)
- DJ Mirum Pharmaceuticals Is Maintained at Buy by Citigroup, from 12:59PM ET on Wednesday Nov 13, 2024 by Dow Jones
  12:59PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: MIRM
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/MIRM/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 13, 2024 12:59 ET (17:59 GMT)
- DJ Mirum Pharmaceuticals Is Maintained at Outperform by Baird, from 7:32AM ET on Wednesday Nov 13, 2024 by Dow Jones
  7:32AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: MIRM
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/MIRM/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 13, 2024 07:32 ET (12:32 GMT)
Nov 12, 2024
- Mirum Pharmaceuticals' Q3 Loss Narrows, Revenue Rises, from 8:23AM ET on Tuesday Nov 12, 2024 by MT Newswires
  8:23AM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: MIRM
  08:23 AM EST, 11/12/2024 (MT Newswires) -- Mirum Pharmaceuticals (MIRM) reported a Q3 net loss Tuesday of $0.30 per share, narrowing from a loss of $0.57 a year earlier. Analysts polled by Capital IQ expected a loss of $0.46 per share. Total revenue...

Nov 21, 2024
- DJ Wave Life Sciences Is Maintained at Outperform by Mizuho, from 8:26AM ET on Thursday Nov 21, 2024 by Dow Jones
  8:26AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: WVE
Nov 20, 2024
- DJ Arrowhead Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co., from 1:17PM ET on Wednesday Nov 20, 2024 by Dow Jones
  1:17PM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: ARWR
Nov 19, 2024
- Top Premarket Gainers, from 7:39AM ET on Tuesday Nov 19, 2024 by MT Newswires
  7:39AM ET on Tuesday Nov 19, 2024 by MT Newswires
  Companies Mentioned: UVE, SYM, XNCR, TRNR, HONE
Nov 18, 2024
- Arrowhead Files Plozasiran New Drug Application in Familial Chylomicronemia Syndrome, from 8:41AM ET on Monday Nov 18, 2024 by MT Newswires
  8:41AM ET on Monday Nov 18, 2024 by MT Newswires
  Companies Mentioned: ARWR
- Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome, from 7:31AM ET on Monday Nov 18, 2024 by Dow Jones
  7:31AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: ARWR
- Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran, from 7:30AM ET on Monday Nov 18, 2024 by Dow Jones
  7:30AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: ARWR
Nov 15, 2024
- Wave Life Sciences to Present at Jefferies London Healthcare Conference, from 8:30AM ET on Friday Nov 15, 2024 by Dow Jones
  8:30AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: WVE
Nov 14, 2024
- --Tudor Pickering Holt Downgrades MannKind to Hold From Buy, Adjusts Price Target to $5.50 From $7, from 12:56PM ET on Thursday Nov 14, 2024 by MT Newswires
  12:56PM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: MNKD
Nov 13, 2024
- Xencor Insider Sold Shares Worth $1,612,639, According to a Recent SEC Filing, from 5:59PM ET on Wednesday Nov 13, 2024 by MT Newswires
  5:59PM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: XNCR
- DJ Wave Life Sciences Price Target Maintained With a $22.00/Share by HC Wainwright & Co., from 9:48AM ET on Wednesday Nov 13, 2024 by Dow Jones
  9:48AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: WVE

Mirum Pharmaceuticals Inc
NASDAQ:MIRMUnited States

Search Criteria

Nov 14, 2024

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

DJ Mirum Pharmaceuticals Price Target Maintained With a $66.00/Share by HC Wainwright & Co., from 2:06PM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Mirum Pharmaceuticals Is Maintained at Buy by Citigroup, from 12:59PM ET on Wednesday Nov 13, 2024 by Dow Jones

DJ Mirum Pharmaceuticals Is Maintained at Outperform by Baird, from 7:32AM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 12, 2024

Mirum Pharmaceuticals' Q3 Loss Narrows, Revenue Rises, from 8:23AM ET on Tuesday Nov 12, 2024 by MT Newswires

Peers Headlines

Nov 21, 2024

DJ Wave Life Sciences Is Maintained at Outperform by Mizuho, from 8:26AM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 20, 2024

DJ Arrowhead Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co., from 1:17PM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 19, 2024

Top Premarket Gainers, from 7:39AM ET on Tuesday Nov 19, 2024 by MT Newswires

Nov 18, 2024

Arrowhead Files Plozasiran New Drug Application in Familial Chylomicronemia Syndrome, from 8:41AM ET on Monday Nov 18, 2024 by MT Newswires

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome, from 7:31AM ET on Monday Nov 18, 2024 by Dow Jones

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran, from 7:30AM ET on Monday Nov 18, 2024 by Dow Jones

Nov 15, 2024

Wave Life Sciences to Present at Jefferies London Healthcare Conference, from 8:30AM ET on Friday Nov 15, 2024 by Dow Jones

Nov 14, 2024

--Tudor Pickering Holt Downgrades MannKind to Hold From Buy, Adjusts Price Target to $5.50 From $7, from 12:56PM ET on Thursday Nov 14, 2024 by MT Newswires

Nov 13, 2024

Xencor Insider Sold Shares Worth $1,612,639, According to a Recent SEC Filing, from 5:59PM ET on Wednesday Nov 13, 2024 by MT Newswires

DJ Wave Life Sciences Price Target Maintained With a $22.00/Share by HC Wainwright & Co., from 9:48AM ET on Wednesday Nov 13, 2024 by Dow Jones